Form 4: Sotera Health Director David Wheadon Receives 19,132 Restricted Stock Units

Sotera Health Company's Director, David E. Wheadon, was granted 19,132 restricted stock units (RSUs) on May 22, 2025, as part of the company's 2020 Omnibus Incentive Plan.

Summary

• David E. Wheadon, a Director of Sotera Health Co (SHC), acquired 19,132 shares of Common Stock on May 22, 2025.
• These securities are Restricted Stock Units (RSUs) granted at a price of $0 per unit.
• Each RSU represents the right to receive one share of Common Stock, subject to vesting conditions.
• The RSUs will vest in full on the earlier of (i) the first anniversary of the grant date (May 22, 2026) or (ii) the date immediately prior to the Issuer's next regular annual shareholders meeting.
• Vesting is contingent upon Mr. Wheadon's continued service as a non-employee director.
• Following this transaction, Mr. Wheadon beneficially owns a total of 74,912 securities, comprising 19,132 RSUs and 55,780 shares of Common Stock.

Sentiment

Score: 7

Explanation: The grant of restricted stock units to a director is a positive sign of alignment between management and shareholder interests, serving as an incentive for continued service and long-term value creation. This is a routine and expected compensation event.

Positives

• The grant of Restricted Stock Units (RSUs) to a non-employee director aligns the director's interests with those of long-term shareholders.
• This equity compensation serves as an incentive for continued service and commitment to the company's performance.

Future Outlook

The granted Restricted Stock Units are subject to vesting conditions, which include continued service as a non-employee director until the earlier of the first anniversary of the grant date or the date immediately prior to the Issuer's next regular annual shareholders meeting.

Industry Context

The grant of Restricted Stock Units to non-employee directors is a common and standard practice across various industries for public companies, serving as a key component of executive and director compensation to align their interests with long-term shareholder value.

Comparison to Industry Standards

• The structure of this RSU grant, including the $0 grant price and vesting conditions tied to continued service, is consistent with typical equity compensation practices for non-employee directors in publicly traded companies across sectors, including healthcare and medical device industries.
• While specific comparable companies are not named in the filing, this type of incentive aligns with compensation strategies seen at peers like STERIS plc or Cantel Medical Corp. (prior to acquisition), which often utilize equity awards to retain and incentivize board members.

Corporate Governance

Related Party Transactions

• The grant of Restricted Stock Units to David E. Wheadon, a Director of Sotera Health Company, constitutes a related party transaction, which is a standard form of compensation for board members and is disclosed as required by SEC regulations.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's financial interests with the long-term performance of the company, potentially benefiting shareholders through improved governance and strategic oversight.
• Employees: While not directly impacting general employees, the use of an omnibus incentive plan indicates a broader framework for equity compensation that may extend to other key personnel.

Next Steps

• Vesting of the 19,132 RSUs will occur on the earlier of May 22, 2026, or the date immediately prior to the Issuer's next regular annual shareholders meeting, subject to continued service.

Key Dates

Recommendation

Keywords

Sotera Health, SHC, Form 4, Restricted Stock Units, RSUs, Insider Transaction, Director Compensation, Equity Grant, Beneficial Ownership, Incentive Plan